Which has higher valuation & earnings, AVXL or IMMX?

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anavex Life Sciences N/A N/A -$46.38M -$0.15 N/A Immix Biopharma N/A N/A -$29.44M -$0.88 N/A

Is AVXL or IMMX more profitable?

Anavex Life Sciences' return on equity of -11.43% beat Immix Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Anavex Life Sciences N/A -11.43% -10.72% Immix Biopharma N/A -38.44% -34.72%

Does the media favor AVXL or IMMX?

In the previous week, Anavex Life Sciences had 1 more articles in the media than Immix Biopharma. MarketBeat recorded 25 mentions for Anavex Life Sciences and 24 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 0.38 beat Anavex Life Sciences' score of 0.05 indicating that Immix Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 2 Very Positive mention(s) 2 Positive mention(s) 17 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Immix Biopharma 6 Very Positive mention(s) 1 Positive mention(s) 16 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, AVXL or FTH?

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anavex Life Sciences N/A N/A -$46.38M -$0.15 N/A Sensei Biotherapeutics N/A N/A -$21.08M -$141.65 N/A

Is AVXL or FTH more profitable?

Anavex Life Sciences' return on equity of -11.43% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Anavex Life Sciences N/A -11.43% -10.72% Sensei Biotherapeutics N/A -1,012.17% -175.69%

Does the media favor AVXL or FTH?

In the previous week, Anavex Life Sciences had 22 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 25 mentions for Anavex Life Sciences and 3 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 0.37 beat Anavex Life Sciences' score of 0.05 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 2 Very Positive mention(s) 2 Positive mention(s) 17 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Sensei Biotherapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is AVTX or AVXL more profitable?

Anavex Life Sciences' return on equity of -11.43% beat Avalo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avalo Therapeutics N/A -58.03% -48.22% Anavex Life Sciences N/A -11.43% -10.72%

Does the media prefer AVTX or AVXL?

In the previous week, Anavex Life Sciences had 21 more articles in the media than Avalo Therapeutics. MarketBeat recorded 25 mentions for Anavex Life Sciences and 4 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.29 beat Anavex Life Sciences' score of 0.05 indicating that Avalo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anavex Life Sciences 2 Very Positive mention(s) 2 Positive mention(s) 17 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media refer more to AVXL or RIGL?

In the previous week, Anavex Life Sciences had 21 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 25 mentions for Anavex Life Sciences and 4 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.81 beat Anavex Life Sciences' score of 0.05 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 2 Very Positive mention(s) 2 Positive mention(s) 17 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral Rigel Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, OLMA or AVXL?

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Olema Pharmaceuticals N/A N/A -$162.45M -$2.12 N/A Anavex Life Sciences N/A N/A -$46.38M -$0.15 N/A

Is OLMA or AVXL more profitable?

Anavex Life Sciences' return on equity of -11.43% beat Olema Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Olema Pharmaceuticals N/A -48.26% -43.04% Anavex Life Sciences N/A -11.43% -10.72%

Does the media refer more to OLMA or AVXL?

In the previous week, Anavex Life Sciences had 23 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 25 mentions for Anavex Life Sciences and 2 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.73 beat Anavex Life Sciences' score of 0.05 indicating that Olema Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Anavex Life Sciences 2 Very Positive mention(s) 2 Positive mention(s) 17 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Anavex Life Sciences (AVXL) Competitors

$1.82 -0.07 (-3.70%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.88 +0.06 (+3.24%)

As of 10/2/2026 07:59 PM Eastern

Compare

AVXL vs. IMMX, FTH, AVTX, RIGL, and OLMA

Should you buy Anavex Life Sciences stock or one of its competitors? Anavex Life Sciences's main competitors and comparable companies include Immix Biopharma (IMMX), Sensei Biotherapeutics (FTH), Avalo Therapeutics (AVTX), Rigel Pharmaceuticals (RIGL), and Olema Pharmaceuticals (OLMA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Anavex Life Sciences compare to Immix Biopharma?

Anavex Life Sciences (NASDAQ:AVXL) and Immix Biopharma (NASDAQ:IMMX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Anavex Life Sciences presently has a consensus target price of $21.33, suggesting a potential upside of 1,072.16%. Immix Biopharma has a consensus target price of $24.14, suggesting a potential upside of 149.41%. Given Anavex Life Sciences' higher probable upside, equities research analysts plainly believe Anavex Life Sciences is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Immix Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78

31.5% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 11.3% of Immix Biopharma shares are owned by institutional investors. 11.4% of Anavex Life Sciences shares are owned by insiders. Comparatively, 30.3% of Immix Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Anavex Life Sciences had 1 more articles in the media than Immix Biopharma. MarketBeat recorded 25 mentions for Anavex Life Sciences and 24 mentions for Immix Biopharma. Immix Biopharma's average media sentiment score of 0.38 beat Anavex Life Sciences' score of 0.05 indicating that Immix Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	2 Very Positive mention(s)	2 Positive mention(s)	17 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Immix Biopharma	6 Very Positive mention(s)	1 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anavex Life Sciences has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market. Comparatively, Immix Biopharma has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.15	N/A
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A

Anavex Life Sciences' return on equity of -11.43% beat Immix Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-11.43%	-10.72%
Immix Biopharma	N/A	-38.44%	-34.72%

Summary

Anavex Life Sciences beats Immix Biopharma on 7 of the 13 factors compared between the two stocks.

How does Anavex Life Sciences compare to Sensei Biotherapeutics?

Anavex Life Sciences (NASDAQ:AVXL) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, dividends, institutional ownership, media sentiment, risk and profitability.

Anavex Life Sciences presently has a consensus price target of $21.33, indicating a potential upside of 1,072.16%. Sensei Biotherapeutics has a consensus price target of $56.25, indicating a potential upside of 98.41%. Given Anavex Life Sciences' higher possible upside, research analysts clearly believe Anavex Life Sciences is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93

31.5% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 11.4% of Anavex Life Sciences shares are owned by insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Anavex Life Sciences had 22 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 25 mentions for Anavex Life Sciences and 3 mentions for Sensei Biotherapeutics. Sensei Biotherapeutics' average media sentiment score of 0.37 beat Anavex Life Sciences' score of 0.05 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	2 Very Positive mention(s)	2 Positive mention(s)	17 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Sensei Biotherapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anavex Life Sciences' return on equity of -11.43% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-11.43%	-10.72%
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%

Anavex Life Sciences has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.29, meaning that its share price is 129% less volatile than the broader market.

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.15	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A

Summary

Anavex Life Sciences beats Sensei Biotherapeutics on 8 of the 14 factors compared between the two stocks.

How does Anavex Life Sciences compare to Avalo Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

In the previous week, Anavex Life Sciences had 21 more articles in the media than Avalo Therapeutics. MarketBeat recorded 25 mentions for Anavex Life Sciences and 4 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.29 beat Anavex Life Sciences' score of 0.05 indicating that Avalo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anavex Life Sciences	2 Very Positive mention(s)	2 Positive mention(s)	17 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Avalo Therapeutics currently has a consensus target price of $45.10, suggesting a potential upside of 200.87%. Anavex Life Sciences has a consensus target price of $21.33, suggesting a potential upside of 1,072.16%. Given Anavex Life Sciences' higher probable upside, analysts plainly believe Anavex Life Sciences is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Anavex Life Sciences' return on equity of -11.43% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Anavex Life Sciences	N/A	-11.43%	-10.72%

Avalo Therapeutics has a beta of 0.68, indicating that its share price is 32% less volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market.

Anavex Life Sciences has lower revenue, but higher earnings than Avalo Therapeutics. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	13,398.56	-$78.26M	-$4.37	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.15	N/A

87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 31.5% of Anavex Life Sciences shares are held by institutional investors. 4.5% of Avalo Therapeutics shares are held by company insiders. Comparatively, 11.4% of Anavex Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Anavex Life Sciences beats Avalo Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Anavex Life Sciences compare to Rigel Pharmaceuticals?

Anavex Life Sciences (NASDAQ:AVXL) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

Anavex Life Sciences presently has a consensus price target of $21.33, indicating a potential upside of 1,072.16%. Rigel Pharmaceuticals has a consensus price target of $59.00, indicating a potential upside of 25.13%. Given Anavex Life Sciences' higher possible upside, research analysts clearly believe Anavex Life Sciences is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

31.5% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 11.4% of Anavex Life Sciences shares are held by company insiders. Comparatively, 10.5% of Rigel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Anavex Life Sciences has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market. Comparatively, Rigel Pharmaceuticals has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market.

In the previous week, Anavex Life Sciences had 21 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 25 mentions for Anavex Life Sciences and 4 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.81 beat Anavex Life Sciences' score of 0.05 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	2 Very Positive mention(s)	2 Positive mention(s)	17 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral
Rigel Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rigel Pharmaceuticals has a net margin of 116.30% compared to Anavex Life Sciences' net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 22.95% beat Anavex Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-11.43%	-10.72%
Rigel Pharmaceuticals	116.30%	22.95%	17.19%

Rigel Pharmaceuticals has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.15	N/A
Rigel Pharmaceuticals	$294.28M	2.96	$367.02M	$16.32	2.89

Summary

Rigel Pharmaceuticals beats Anavex Life Sciences on 12 of the 15 factors compared between the two stocks.

How does Anavex Life Sciences compare to Olema Pharmaceuticals?

Olema Pharmaceuticals (NASDAQ:OLMA) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Olema Pharmaceuticals has a beta of 2, indicating that its share price is 100% more volatile than the broader market. Comparatively, Anavex Life Sciences has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market.

In the previous week, Anavex Life Sciences had 23 more articles in the media than Olema Pharmaceuticals. MarketBeat recorded 25 mentions for Anavex Life Sciences and 2 mentions for Olema Pharmaceuticals. Olema Pharmaceuticals' average media sentiment score of 1.73 beat Anavex Life Sciences' score of 0.05 indicating that Olema Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Olema Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Anavex Life Sciences	2 Very Positive mention(s)	2 Positive mention(s)	17 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Anavex Life Sciences' return on equity of -11.43% beat Olema Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Olema Pharmaceuticals	N/A	-48.26%	-43.04%
Anavex Life Sciences	N/A	-11.43%	-10.72%

91.8% of Olema Pharmaceuticals shares are held by institutional investors. Comparatively, 31.5% of Anavex Life Sciences shares are held by institutional investors. 12.6% of Olema Pharmaceuticals shares are held by insiders. Comparatively, 11.4% of Anavex Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Anavex Life Sciences is trading at a lower price-to-earnings ratio than Olema Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Olema Pharmaceuticals	N/A	N/A	-$162.45M	-$2.12	N/A
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.15	N/A

Olema Pharmaceuticals presently has a consensus target price of $40.60, indicating a potential upside of 393.32%. Anavex Life Sciences has a consensus target price of $21.33, indicating a potential upside of 1,072.16%. Given Anavex Life Sciences' higher probable upside, analysts clearly believe Anavex Life Sciences is more favorable than Olema Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Olema Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Olema Pharmaceuticals beats Anavex Life Sciences on 7 of the 13 factors compared between the two stocks.

Get Anavex Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVXL vs. The Competition

Export

Metric	Anavex Life Sciences	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$175.20M	$3.87B	$7.14B	$13.22B
Dividend Yield	N/A	3.64%	2.53%	16.78%
P/E Ratio	-12.13	13.13	275.97	26.04
Price / Sales	N/A	1,434.36	672.88	109.45
Price / Cash	N/A	122.60	77.60	51.75
Price / Book	1.65	16.63	10.93	6.31
Net Income	-$46.38M	-$22.71M	$3.51B	$362.16M
7 Day Performance	-23.53%	-2.99%	-2.00%	-1.66%
1 Month Performance	-36.14%	-10.60%	-6.15%	-4.50%
1 Year Performance	-81.73%	19.44%	7.44%	2.06%

Anavex Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVXL Anavex Life Sciences	1.3262 of 5 stars	$1.82 -3.7%	$21.33 +1,072.2%	-80.1%	$175.20M	N/A	N/A	34	Trending News High Trading Volume
IMMX Immix Biopharma	3.1099 of 5 stars	$12.47 -0.2%	$22.86 +83.3%	+361.0%	$894.24M	N/A	N/A	21	Positive News Analyst Forecast
FTH Sensei Biotherapeutics	2.6074 of 5 stars	$33.29 -3.5%	$56.25 +69.0%	N/A	$891.49M	N/A	N/A	29
AVTX Avalo Therapeutics	2.4328 of 5 stars	$16.17 -2.4%	$45.10 +178.9%	+15.3%	$888.65M	$60K	N/A	33
RIGL Rigel Pharmaceuticals	3.8445 of 5 stars	$47.09 +1.0%	$59.00 +25.3%	+67.7%	$862.94M	$294.28M	2.89	174	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVXL) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anavex Life Sciences (AVXL) Competitors

AVXL vs. IMMX, FTH, AVTX, RIGL, and OLMA

How does Anavex Life Sciences compare to Immix Biopharma?

Summary

How does Anavex Life Sciences compare to Sensei Biotherapeutics?

Summary

How does Anavex Life Sciences compare to Avalo Therapeutics?

Summary

How does Anavex Life Sciences compare to Rigel Pharmaceuticals?

Summary

How does Anavex Life Sciences compare to Olema Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL vs. The Competition

Anavex Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anavex Life Sciences (AVXL) Competitors

AVXL vs. IMMX, FTH, AVTX, RIGL, and OLMA

How does Anavex Life Sciences compare to Immix Biopharma?

Do analysts prefer AVXL or IMMX?

Do institutionals and insiders have more ownership in AVXL or IMMX?

Does the media favor AVXL or IMMX?

Which has more risk & volatility, AVXL or IMMX?

Which has higher valuation & earnings, AVXL or IMMX?

Is AVXL or IMMX more profitable?

Summary

How does Anavex Life Sciences compare to Sensei Biotherapeutics?

Do analysts recommend AVXL or FTH?

Do insiders & institutionals believe in AVXL or FTH?

Does the media favor AVXL or FTH?

Is AVXL or FTH more profitable?

Which has more volatility & risk, AVXL or FTH?

Which has preferable valuation & earnings, AVXL or FTH?

Summary

How does Anavex Life Sciences compare to Avalo Therapeutics?

Does the media prefer AVTX or AVXL?

Do analysts recommend AVTX or AVXL?

Is AVTX or AVXL more profitable?

Which has more volatility and risk, AVTX or AVXL?

Which has preferable earnings & valuation, AVTX or AVXL?

Do institutionals & insiders have more ownership in AVTX or AVXL?

Summary

How does Anavex Life Sciences compare to Rigel Pharmaceuticals?

Do analysts recommend AVXL or RIGL?

Do institutionals & insiders hold more shares of AVXL or RIGL?

Which has more volatility and risk, AVXL or RIGL?

Does the media refer more to AVXL or RIGL?

Is AVXL or RIGL more profitable?

Which has stronger earnings & valuation, AVXL or RIGL?

Summary

How does Anavex Life Sciences compare to Olema Pharmaceuticals?

Which has more volatility & risk, OLMA or AVXL?

Does the media refer more to OLMA or AVXL?

Is OLMA or AVXL more profitable?

Do insiders and institutionals hold more shares of OLMA or AVXL?

Which has higher earnings and valuation, OLMA or AVXL?

Do analysts prefer OLMA or AVXL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVXL vs. The Competition

Anavex Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools